DarklyCharming
Established Member
- Reaction score
- 1
I was going to take a month off from posting but wanted to come back and post some news I came across.
Brief reminder: Intercytex is the UK based company that is developing Trichocyte, which is cellular implantation that spurs hair growth. They have finished Phase I testing of their product and are currently beginning Phase II.
Here is the new information that I don't think has been posted on here yet.
1. Intercytex has entered an agreement to allow Bosley International to market Trichocyte in the US. Granted, there are a lot of anti-Bosley posts on this forum but I think it's a good sign that they have already begun their efforts to begin marketing in the US. This means that when the product is ready to go, it will fly through the markets. Also, this lends the research between Bosley and Intercytex to be shared.
2. Intercytex is sharing their scientific advancements with Harvard University and Hiroshima. Top minds of cellular science are working together on this.
3. There is a pipeline announcement coinciding with their new CEO's arrival, dated January 10th, 2005. Here is an exerpt:
"Its development portfolio includes three wound care and two hair regeneration products including ICX-P to accelerate wound healing (in Phase II) and ICX-T, a potential treatment for hair loss, which is intended to be used alone or in combination with hair transplantation (in Phase I). The first market launch is planned for ICX-P in 2008 and the development pipeline is expected to deliver a series of products to market by 2010. "
ICX-P is their product ProtoDerm.
IXC-T is TrichoCyte.
End Summary: TrichoCyte is anticipated for the consumer by 2010.
Brief reminder: Intercytex is the UK based company that is developing Trichocyte, which is cellular implantation that spurs hair growth. They have finished Phase I testing of their product and are currently beginning Phase II.
Here is the new information that I don't think has been posted on here yet.
1. Intercytex has entered an agreement to allow Bosley International to market Trichocyte in the US. Granted, there are a lot of anti-Bosley posts on this forum but I think it's a good sign that they have already begun their efforts to begin marketing in the US. This means that when the product is ready to go, it will fly through the markets. Also, this lends the research between Bosley and Intercytex to be shared.
2. Intercytex is sharing their scientific advancements with Harvard University and Hiroshima. Top minds of cellular science are working together on this.
3. There is a pipeline announcement coinciding with their new CEO's arrival, dated January 10th, 2005. Here is an exerpt:
"Its development portfolio includes three wound care and two hair regeneration products including ICX-P to accelerate wound healing (in Phase II) and ICX-T, a potential treatment for hair loss, which is intended to be used alone or in combination with hair transplantation (in Phase I). The first market launch is planned for ICX-P in 2008 and the development pipeline is expected to deliver a series of products to market by 2010. "
ICX-P is their product ProtoDerm.
IXC-T is TrichoCyte.
End Summary: TrichoCyte is anticipated for the consumer by 2010.